Clinical trials: Rituximab, completed
Diffuse Large B-cell Lymphoma
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
- Trial name
- B-MIND (NCT02763319)
- Testing
- Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
- Where
- 158 sites in United States, Australia and 21 more
- Volunteers
- 453 people
- Sponsor
- Incyte Corporation
Non-Hodgkins Lymphoma
CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma
This study will assess the toxicity/safety of CHOP chemotherapy given concurrently with rituximab, followed by maintenance PEG Intron in patients with anthracycline naïve indolent non-Hodgkin's lymphoma.
- Trial name
- NCT00574730
- Testing
- CHOP/Rituximab, PEG INTRON
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Nebraska
Lymphoma
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia.
- Trial name
- NCT00667329
- Testing
- 2CdA, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, and vincristine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00726700
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Volunteers
- 109 people
- Sponsor
- Universität des Saarlandes
Lymphoma
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
RATIONALE: To evaluate the efficacy of a new high intensity chemotherapy regimen with thalidomide maintenance in patients with newly diagnosed mantle cell lymphoma PURPOSE: This phase II trial is studying how well giving…
- Trial name
- NCT00450801
- Testing
- Rituximab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Miami
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
This is a Phase I, multicenter, open-label, dose-escalation study of DCDT2980S administered by intravenous (IV) infusion to patients with relapsed or refractory hematologic malignancies.
- Trial name
- NCT01209130
- Testing
- DCDT2980S, rituximab
- Where
- 9 sites in United States
- Volunteers
- 91 people
- Sponsor
- Genentech, Inc.
Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma
Conventional therapy is effective for diffuse aggressive lymphomas and low grade lymphomas, but is limited by relapse occurs in 40 to 50% of subjects.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Transformed Lymphoma
- Trial name
- NCT00225212
- Testing
- Rituximab 375 mg/m2
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
Mantle-Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients…
- Trial name
- NCT00878254
- Testing
- G-CSF, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
IgA Nephropathy
Rituximab and RASi in Patients with IgAN
A study to evaluate safety and activity in treatment of IgAN patients using Rituximab in combination with RASi(ACEI and/or ARB) compared with RASi.
- Trial name
- RITA (NCT04525729)
- Testing
- Rituximab, RAS 2410
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Nan Chen,MD
Hairy Cell Leukemia (HCL)
Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab
The study will test the effectiveness (rate of complete remissions, total remission rate and duration of remission) and toxicity of the combined immuno/chemotherapy with subcutaneous cladribine (LITAK®) plus anti-CD20* antibody…
- Trial name
- NCT02157181
- Testing
- 2CdA +/- Rituximab
- Where
- 47 sites in Germany
- Volunteers
- 89 people
- Sponsor
- Jurgen Barth
Non-Hodgkin's Lymphoma
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkin's lymphoma (NHL) or refractory NHL, and to test the immunity of study subjects after receiving four treatments with rituximab.
- Trial name
- NCT00090038
- Testing
- rituximab
- Where
- 45 sites in United States, Austria and 9 more
- Volunteers
- 168 people
- Sponsor
- Biogen
Diffuse Large B-Cell Lymphoma (DLBCL), Follicular NHL Grade 3b
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13
This is a randomized, open label, phase III study to evaluate the ability of rituximab maintenance therapy to prolong event-free survival in aggressive NHL.
- Trial name
- NCT00400478
- Testing
- Rituximab
- Where
- 131 sites in Australia, Austria and 24 more
- Volunteers
- 683 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Lymphoma
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004889
- Testing
- rituximab
- Where
- 8 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Idiopathic Membranous Nephropathy
Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
The Membranous Nephropathy is one of the most common cause of Nephrotic Syndrome of adults. In 2/3 of patients the cause of the disease is idiopathic.
- Trial name
- GEMRITUX (NCT01508468)
- Testing
- symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin), experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
B-cell Small Lymphocytic Lymphoma Recurrent
A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma
This was a Phase 1 multicenter study of bendamustine, rituximab and TRU-016 (BRT) in subjects with relapsed indolent B-cell lymphoma.
- Trial name
- NCT01317901
- Testing
- TRU-016, Bendamustine, Rituximab
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aptevo Therapeutics
Kidney Transplantation, Rituximab (RTx)
Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
This project comprises immunological and virological analyses within a prospective clinical study of Rituximab (Rtx)-treated blood group incompatible living donor (LD) renal transplant recipients compared to blood group…
- Conditions
- Kidney Transplantation, Rituximab (RTx), Living Donors, Immunology
- Trial name
- NCT01136395
- Testing
- Rituximab, living donor transplantation, deceased donor transplantation
- Where
- Germany
- Volunteers
- 85 people
- Sponsor
- University of Giessen
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Lymphoma, Large B-Cell, Diffuse
Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide with R-GemOx(rituximab、gemcitabine plus oxaliplatin) regimen in the treatment of transplant-ineligible…
- Trial name
- NCT04022005
- Testing
- Chidamide, Rituximab, Gemcitabine,Oxaliplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Sun Yat-sen University
Renal Transplant, Autoimmune Diseases
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
Rituximab (a monoclonal antibody raised against CD20) is used to treat various immune disorders. In some cases such as treatment of humoral acute rejection of renal transplant, thrombotic thrombocytopenic purpura, vasculitis or…
- Trial name
- PK-rituximab (NCT00820469)
- Testing
- Rituximab 375, rituximab 1000
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Toulouse
Kidney Failure, Chronic, Renal Insufficiency
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor.
- Trial name
- NCT02314403
- Testing
- Belatacept, ATG, Rituximab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.